The company has a market-cap of $407.7 million.
BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.
MeiraGTx Holdings plc provided the following description of their company for its IPO: ” We are a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. “.
MeiraGTx Holdings plc was founded in 2015 and has 59 employees. The company is located at 430 East 29th Street, 10th Floor, New York, NY 10016, US and can be reached via phone at (646) 490-2965. or on the web at http://www.meiragtx.com.
Receive News & Ratings for MeiraGTx Holdings plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx Holdings plc and related companies with MarketBeat.com's FREE daily email newsletter.